Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AbCellera Biologics Inc. (ABCL : NSDQ)

• Company Description    AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada. Number of Employees: 562

• Price / Volume Information    Yesterday's Closing Price: $5.20 Daily Weekly Monthly 20 Day Moving Average: 10,165,724 shares Shares Outstanding: 305.38 (millions) Market Capitalization: $1,587.95 (millions) Beta: 1.02 52 Week High: $6.52 52 Week Low: $1.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 28.40% 22.12% 12 Week 44.85% 33.90% Year To Date 52.05% 38.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 150 W 4TH AVENUE - VANCOUVER,A1 V5Y 1G6 CAN ph: 604-559-9005 fax: - ir@abcellera.com http://www.abcellera.com

• General Corporate Information    Officers Carl L. G. Hansen - Chief Executive Officer and Director Andrew Booth - Chief Financial Officer Stephen R. Quake - Director Michael Hayden - Director John S. Montalbano - Director Peer Information AbCellera Biologics Inc. (CORR.) AbCellera Biologics Inc. (RSPI) AbCellera Biologics Inc. (CGXP) AbCellera Biologics Inc. (BGEN) AbCellera Biologics Inc. (GTBP) AbCellera Biologics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00288U106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 305.38 Most Recent Split Date: (:1) Beta: 1.02 Market Capitalization: $1,587.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.69 Price/Cash Flow: - Price / Sales: 20.05 EPS Growth vs. Year Ago Period: 6.67% vs. Previous Quarter: -366.67% Sales Growth vs. Year Ago Period: 96.34% vs. Previous Quarter: -81.46% ROE 03/31/26 - -14.86 12/31/25 - -15.05 09/30/25 - -17.21 ROA 03/31/26 - -10.62 12/31/25 - -10.92 09/30/25 - -12.76 Current Ratio 03/31/26 - 14.05 12/31/25 - 11.32 09/30/25 - 10.10 Quick Ratio 03/31/26 - 14.05 12/31/25 - 11.32 09/30/25 - 10.10 Operating Margin 03/31/26 - -181.75 12/31/25 - -198.37 09/30/25 - -493.42 Net Margin 03/31/26 - -181.75 12/31/25 - -198.37 09/30/25 - -493.42 Pre-Tax Margin 03/31/26 - -219.86 12/31/25 - -236.39 09/30/25 - -580.13 Book Value 03/31/26 - 3.07 12/31/25 - 3.23 09/30/25 - 3.23 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©